SpectraCure AB Asset Resilience Ratio
SpectraCure AB asset resilience ratio. SpectraCure AB (SPEC) has an Asset Resilience Ratio of 12.95% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SPEC days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of SpectraCure AB (2016–2025)
Asset resilience ratio of SpectraCure AB from 2016 to 2025. This chart shows how SpectraCure AB's Asset Resilience Ratio has changed over time. Read SPEC total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down SpectraCure AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SPEC total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr13.53 Million | 12.95% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr13.53 Million | 12.95% |
Asset Resilience Insights
- Moderate Liquidity: SpectraCure AB has 12.95% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
SpectraCure AB Industry Peers by Asset Resilience Ratio
Compare SpectraCure AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
SpectraCure AB Asset Resilience Ratio by Year (2016–2025)
SpectraCure AB asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for SpectraCure AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.95% | Skr13.53 Million ≈ $1.46 Million |
Skr104.47 Million ≈ $11.24 Million |
-2.16pp |
| 2024-12-31 | 15.10% | Skr18.27 Million ≈ $1.97 Million |
Skr121.00 Million ≈ $13.02 Million |
-24.22pp |
| 2023-12-31 | 39.32% | Skr56.95 Million ≈ $6.13 Million |
Skr144.83 Million ≈ $15.59 Million |
-18.05pp |
| 2022-12-31 | 57.37% | Skr93.18 Million ≈ $10.03 Million |
Skr162.42 Million ≈ $17.48 Million |
-10.70pp |
| 2021-12-31 | 68.07% | Skr129.69 Million ≈ $13.96 Million |
Skr190.52 Million ≈ $20.50 Million |
-6.61pp |
| 2020-12-31 | 74.69% | Skr157.24 Million ≈ $16.92 Million |
Skr210.53 Million ≈ $22.66 Million |
+20.58pp |
| 2019-12-31 | 54.10% | Skr54.21 Million ≈ $5.83 Million |
Skr100.19 Million ≈ $10.78 Million |
-11.27pp |
| 2018-12-31 | 65.38% | Skr45.08 Million ≈ $4.85 Million |
Skr68.95 Million ≈ $7.42 Million |
+48.79pp |
| 2017-12-31 | 16.59% | Skr2.44 Million ≈ $262.60K |
Skr14.71 Million ≈ $1.58 Million |
+15.26pp |
| 2016-12-31 | 1.33% | Skr381.67K ≈ $41.07K |
Skr28.77 Million ≈ $3.10 Million |
-- |
About SpectraCure AB
SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.